Blue Jet Healthcare Full Year 2025 Earnings: Beats Expectations
Blue Jet Healthcare (NSE:BLUEJET) Full Year 2025 Results
Key Financial Results
- Revenue: ₹10.8b (up 51% from FY 2024).
- Net income: ₹3.05b (up 86% from FY 2024).
- Profit margin: 28% (up from 23% in FY 2024). The increase in margin was driven by higher revenue.
- EPS: ₹17.59 (up from ₹9.44 in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Blue Jet Healthcare Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%.
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are up 16% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 2 warning signs for Blue Jet Healthcare (of which 1 is a bit unpleasant!) you should know about.
If you're looking to trade Blue Jet Healthcare, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Blue Jet Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:BLUEJET
Blue Jet Healthcare
Engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products.
Flawless balance sheet with solid track record.
Market Insights
Community Narratives
